

A1
Cm'd.
which is a continuation of Application Serial No. 08/240,720,
filed on September 16, 1994 and issued as U.S. Patent 5,705,401
on January 6, 1998--.

Please amend the specification as follows:

Page 21, line 12, following "...GAD" insert -- (SEQ ID
NO:1) --.

Page 29, line 16, following "...PLA" insert -- (SEQ ID
NO:2) --.

Page 32, line 21, following "...KTH" insert -- (SEQ ID
NO:3) --; and

Page 32, line 22, following "...RER" insert -- (SEQ ID
NO:4) --.

IN THE CLAIMS

Please cancel claims 1-14 and 22-24 without prejudice.

Please amend the claims as follows:

A2
Cm't
15. (Amended) A method for treating Alzheimer's
disease in a patient, comprising subjecting said patient to a
means [for modulating] which modulates the interaction between a
divalent or trivalent cation and/or heparin [interaction] with
amyloid precursor protein (APP) [APP] in said patient.

16. (Amended) The method according to claim 15 or 25,
wherein the cation is a divalent cation [and is zinc].

17. (Amended) The method according to claim 16 wherein
a therapeutically effective amount of a zinc binding agent is
administered to said patient[, which agent is capable of binding
zinc and thereby modulating its interaction with APP].